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Idiopathic Pulmonary Fibrosis — A Sticky Business
Richard C. Boucher, M.D.
Pulmonary fibrosis comprises a spectrum of dis-
ease phenotypes, including familial and idiopathic 
forms. Current research suggests that pulmo-
nary fibrosis is a “two-hit” disease: a genetic pre-
disposition to abnormal alveolar epithelial-cell 
regulation of the cell cycle and apoptosis com-
bined with environmental stressors, including 
exposure to known fibrogenic materials (e.g., 
asbestos, silica, and cigarette smoke).1 Indeed, 
the identification of mutations in genes expressed 
in alveolar epithelia in association with pulmo-
nary fibrosis — such as the surfactant proteins A 
and C (SPA and SPC, respectively)2,3 — and genes 
associated with cell stability — such as telomer-
ase4 (hTERT and hTER) — have reinforced the no-
tion that the genetic contribution to pulmonary 
fibrosis reflects abnormalities in the homeosta-
sis of alveolar epithelial cells. Hence, it comes as 
a surprise that the linkage and fine-mapping 
data reported by Seibold et al. in this issue of the 
Journal show that a variant single-nucleotide poly-
morphism (SNP) in the promoter region of an 
airway mucin gene (MUC5B) is associated with 
greatly increased production of MUC5B — and 
with pulmonary fibrosis.5
If MUC5B is a mucin secreted into the airway 
and pulmonary fibrosis reflects a lack of cellu-
lar homeostasis in alveolar epithelia, how do we 
connect these observations? Surprisingly little is 
known about the communication between the 
alveolar and terminal bronchiolar surfaces, be-
cause this juncture resides deep in the lung and 
is difficult to study. It is likely that surfactant 
moves off of alveolar surfaces and onto bron-
chiolar surfaces and that alveolar macrophages 
migrate onto bronchiolar surfaces. However, 
whether inhaled soluble toxins — or indeed, al-
veolar surface liquids — are normally cleared 
from alveolar surfaces and transferred to bron-
chiolar surfaces is not known. Also unknown is 
whether there is normally retrograde flow of air-
way mucins into alveoli, although biophysical 
analyses suggest that this is unlikely.
Even with these uncertainties, however, there 
are ways to conceive of bronchiolar–alveolar in-
teractions in pulmonary fibrosis. First, as suggest-
ed by Seibold et al., increased secretion of MUC5B 
may lead to bronchiolar plugging, producing a 
chronic inflammatory and toxic burden on the 
alveolar surface. Indeed, recent biophysical stud-
ies suggest that increased concentrations of 
mucin (4 to 6 times the normal concentration) 
destabilize the mucus clearance system and pro-
mote mucus stasis. Second, MUC5B contains hy-
drophobic domains that organize a host defense 
complex of 40 to 100 proteins, and it is possible 
that hypersecretion of MUC5B with this protein 
complex leads to a persistent host–defense im-
balance favoring excessive inflammation and 
alveolar damage. Clearly, however, this is not the 
whole story, because the mucus plugging caused 
by MUC5B in chronic obstructive pulmonary dis-
ease and cystic fibrosis is not associated with a 
pulmonary fibrosis phenotype.
An intriguing alternative possibility that may 
link a dysfunction of airway secretory cells with 
alveolar cells is the unfolded-protein response, 
which is initiated by diverse stimuli that together 
can produce proinflammatory and proapoptotic 
states. The mutations in SPC and SPA that are as-
sociated with pulmonary fibrosis lead to dys-
function in alveolar type II cells that is probably 
caused by misfolded proteins, endoplasmic-retic-
ulum retention, and unfolded-protein responses.6 
Recent data have shown that the metabolic path-
way for an unfolded-protein response, which is 
dependent on the inositol-requiring enzyme 1β, is 
up-regulated consequent to increased mucin bio-
synthesis.7 Hence, it is conceivable that different 
genetic defects affecting airway cells and alveo-
lar cells collectively produce a chronic unfolded-
protein response in the alveolar–bronchiolar zone. 
Indeed, one study provided strong evidence for 
the importance of a chronic unfolded-protein re-
sponse and a proapoptotic state in the lungs of 
patients with familial pulmonary fibrosis or idio-
pathic pulmonary fibrosis.8
Superimposed on the multiple genes that 
feed into genetic predisposition may be multiple 
pathways that are affected by environmental 
stressors. Clues to the nature of these environ-
mental stressors are revealed in the heterogene-
ity of disease in the lung with pulmonary fibro-
sis. Cigarette smoke is a risk factor for pulmonary 
fibrosis and produces heterogeneous disease in 
chronic obstructive pulmonary disease, reflect-
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ing, in part, the heterogeneity of distribution of 
inhaled toxicants. Microaspiration and viral in-
fection also typically produce heterogeneous lung 
disease. Indeed, there is strong evidence that mi-
croaspiration contributes to the risk of pulmo-
nary fibrosis and produces heterogeneous injury 
in bronchiolar—alveolar units.9 Similarly, viral 
infections may trigger the pulmonary fibrosis 
phenotype in patients with defined underlying 
genetic causes of pulmonary fibrosis (e.g., mu-
tations in SPC).6 Intriguingly, viruses produce 
unfolded-protein responses in healthy cells, and 
viral infection of cells expressing SPC variants as-
sociated with pulmonary fibrosis produced syn-
ergistic unfolded-protein–apoptotic responses, 
suggesting that viruses trigger an unfolded-pro-
tein response that crosses the threshold required 
to produce the pulmonary fibrosis phenotype.10
Like many successful genomewide linkage 
studies, the report by Seibold et al. provides a 
provocative stimulus for broadening our under-
standing of the pathogenesis of pulmonary fi-
brosis. It is likely that the “two-hit” hypothesis 
— one from genetic variation and one from en-
vironmental stressors — is generally correct but 
not complete. It must be modified to account for 
additional genetic and environmental influences. 
A better understanding of the pathogenesis of 
pulmonary fibrosis now may also require an un-
derstanding of the normal commerce between 
alveolar and bronchiolar surfaces. This study 
will stimulate investigations of the effects of the 
MUC5B variant on secretion rates of MUC5B in 
quantitative cell systems, the ectopic expression 
of MUC5B in alveolar epithelia in patients with 
this genetic variation, goblet-cell unfolded-pro-
tein responses in patients with and without this 
polymorphism, and other genes or environmental 
stressors that produce pulmonary fibrosis pheno-
types in patients who do not express the variant 
SNP. In addition, the study dictates that we broad-
en our vision of pulmonary fibrosis therapeutics, 
particularly given the absence of satisfactory 
clinical responses to immunosuppressants and 
corticosteroids. Thus, agents in clinical develop-
ment that may regulate the unfolded-protein re-
sponse may be worthy of early trials in pulmonary 
fibrosis. Similarly, agents that reduce MUC5B 
transcriptional activity in vitro should be tested 
for activity in vivo, including in subjects express-
ing the variant genotype. Thus, the study by Sei-
bold et al. may have “unstuck” our thought pro-
cesses with respect to a disease that has frustrated 
both patients and their physicians.
Disclosure forms provided by the author are available with the 
full text of this article at NEJM.org.
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Truly Emerging — A New Disease Caused by a Novel Virus
Heinz Feldmann, M.D.
Contrary to predictions of the mid-20th century, 
infectious diseases are on the rise, threatening 
human and animal health on both local and 
global scales. Multiple factors are contributing 
to the emergence or reemergence of infectious 
diseases, including increasing human intrusion 
into the natural environment, with behavioral 
changes associated with expanding economic 
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